The Challenge of Managing Atopic Dermatitis in the United States.
暂无分享,去创建一个
Timothy W. Smith | S. Feldman | L. Cox | R. Gerber | J. Cappelleri | L. Strowd | D. Sierka | S. Faulkner | M. Levenberg | S. Feldman
[1] J. Peter,et al. Institute for Clinical and Economic Review , 2021, The Right Price.
[2] J. Silverberg,et al. Baricitinib in adult patients with moderate‐to‐severe atopic dermatitis: A phase 2 parallel, double‐blinded, randomized placebo‐controlled multiple‐dose study , 2018, Journal of the American Academy of Dermatology.
[3] A. Muraro,et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[4] D. Margolis,et al. Epidemiology of atopic dermatitis in adults: Results from an international survey , 2018, Allergy.
[5] A. Muraro,et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I , 2018, Journal of the European Academy of Dermatology and Venereology : JEADV.
[6] C. Flohr,et al. Efficacy and safety of lebrikizumab (an anti‐IL‐13 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo‐controlled phase II trial (TREBLE) , 2018, Journal of the American Academy of Dermatology.
[7] M. Lebwohl,et al. Efficacy and safety of fezakinumab (an IL‐22 monoclonal antibody) in adults with moderate‐to‐severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double‐blind, phase 2a trial , 2018, Journal of the American Academy of Dermatology.
[8] S. Feldman,et al. A safety review of the medications used to treat atopic dermatitis , 2018, Expert opinion on drug safety.
[9] L. Kemény,et al. Adult Atopic Dermatitis is Associated with Increased Aortic Stiffness , 2018, American Journal of Clinical Dermatology.
[10] R. Emsley,et al. Intentional and Unintentional Medication Non-Adherence in Psoriasis: The Role of Patients’ Medication Beliefs and Habit Strength , 2017, The Journal of investigative dermatology.
[11] J. Silverberg,et al. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. , 2018, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[12] J. Gelfand,et al. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey , 2018, Journal of the American Academy of Dermatology.
[13] J. Silverberg,et al. A Phase 2b Dose-Ranging Efficacy and Safety Study of Tralokinumab in Adult Patients with Moderate to Severe Atopic Dermatitis , 2018 .
[14] M. Lebwohl,et al. Expert Perspectives on Management of Moderate-to-Severe Atopic Dermatitis: A Multidisciplinary Consensus Addressing Current and Emerging Therapies. , 2017, The journal of allergy and clinical immunology. In practice.
[15] Timothy W. Smith,et al. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2% , 2017, Journal of medical economics.
[16] J. Fowler,et al. Long‐term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis , 2017, Journal of the American Academy of Dermatology.
[17] Alvin W. Li,et al. Topical Corticosteroid Phobia in Atopic Dermatitis: A Systematic Review , 2017, JAMA dermatology.
[18] S. Sullivan,et al. Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults , 2017, Dermatology and Therapy.
[19] K. Kabashima,et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled, phase II study , 2017, The British journal of dermatology.
[20] J. Gelfand,et al. Impact of atopic dermatitis on health‐related quality of life and productivity in adults in the United States: An analysis using the National Health and Wellness Survey , 2017, Journal of the American Academy of Dermatology.
[21] J. Chao,et al. Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases , 2017, Advances in Therapy.
[22] V. Nambudiri,et al. Research Techniques Made Simple: Cost-Effectiveness Analysis. , 2017, The Journal of investigative dermatology.
[23] K. Heitmiller,et al. An Update on the Pathophysiology of Atopic Dermatitis. , 2017, Dermatologic clinics.
[24] J. Piercy,et al. Discordance Between Physician- and Patient-Reported Disease Severity in Adults with Atopic Dermatitis: A US Cross-Sectional Survey , 2017, American Journal of Clinical Dermatology.
[25] Thomas Bieber,et al. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? , 2017, The Journal of allergy and clinical immunology.
[26] M. Boguniewicz,et al. Current guidelines for the evaluation and management of atopic dermatitis: A comparison of the Joint Task Force Practice Parameter and American Academy of Dermatology guidelines , 2017, The Journal of allergy and clinical immunology.
[27] D. Leung,et al. Assessing the current treatment of atopic dermatitis: Unmet needs. , 2017, The Journal of allergy and clinical immunology.
[28] S. Feldman,et al. Treatment Adherence Intervention Studies in Dermatology and Guidance on How to Support Adherence , 2017, American Journal of Clinical Dermatology.
[29] M. Suárez-Fariñas,et al. Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis , 2017, Experimental dermatology.
[30] M. Ardeleanu,et al. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. , 2017, The New England journal of medicine.
[31] Erika Sevetson,et al. The Burden of Atopic Dermatitis: Summary of a Report for the National Eczema Association. , 2017, The Journal of investigative dermatology.
[32] J. Silverberg,et al. Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder. , 2017, The Journal of investigative dermatology.
[33] L. Strowd,et al. The Future of Atopic Dermatitis Treatment. , 2017, Advances in experimental medicine and biology.
[34] J. Thyssen,et al. Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. , 2017, The New England journal of medicine.
[35] S. Feldman,et al. Adherence in Atopic Dermatitis. , 2019, Advances in experimental medicine and biology.
[36] M. Lebwohl,et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults. , 2016, Journal of the American Academy of Dermatology.
[37] A. Qureshi,et al. Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis: The National Eczema Association Burden of Disease Audit. , 2016, JAMA dermatology.
[38] E. Simpson,et al. Assessing the New and Emerging Treatments for Atopic Dermatitis. , 2016, Seminars in cutaneous medicine and surgery.
[39] Stephan Weidinger,et al. Atopic dermatitis , 2016, The Lancet.
[40] S. Feldman,et al. A review of patient adherence to topical therapies for treatment of atopic dermatitis. , 2015, Cutis.
[41] J. Silverberg. Health Care Utilization, Patient Costs, and Access to Care in US Adults With Eczema: A Population-Based Study. , 2015, JAMA dermatology.
[42] A. Hebert,et al. Diagnosis of Atopic Dermatitis: Mimics, Overlaps, and Complications , 2015, Journal of clinical medicine.
[43] J. Ring,et al. Safety and Efficacy of Pimecrolimus in Atopic Dermatitis: A 5-Year Randomized Trial , 2015, Pediatrics.
[44] J. Kichler,et al. Psoriasis in childhood: effective strategies to improve treatment adherence , 2015, Psoriasis.
[45] S. Takeuchi,et al. Poor adherence to oral and topical medication in 3096 dermatological patients as assessed by the Morisky Medication Adherence Scale-8 , 2014, The British journal of dermatology.
[46] P. Audet,et al. A Review of Approaches for the Management of Specialty Pharmaceuticals in the United States , 2014, PharmacoEconomics.
[47] S. Feldman,et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. , 2014, Journal of the American Academy of Dermatology.
[48] S. Feldman,et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. , 2014, Journal of the American Academy of Dermatology.
[49] J. Silverberg,et al. Associations of Childhood Eczema Severity: A US Population-Based Study , 2014, Dermatitis : contact, atopic, occupational, drug.
[50] Simon Francis Thomsen,et al. Atopic Dermatitis: Natural History, Diagnosis, and Treatment , 2014, ISRN allergy.
[51] S. Feldman,et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. , 2014, Journal of the American Academy of Dermatology.
[52] S. Sullivan,et al. Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. , 2014, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[53] J. Silverberg,et al. Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study. , 2013, The Journal of allergy and clinical immunology.
[54] E. Simpson,et al. Mental health comorbidity in patients with atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.
[55] S. Spector,et al. Atopic dermatitis: a practice parameter update 2012. , 2013, The Journal of allergy and clinical immunology.
[56] M. Chan-yeung,et al. Atopic dermatitis in a high-risk cohort: natural history, associated allergic outcomes, and risk factors. , 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[57] E. Simpson. Comorbidity in Atopic Dermatitis , 2012, Current Dermatology Reports.
[58] L. Misery,et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency , 2011, The British journal of dermatology.
[59] M. Chren,et al. Quality-of-life outcomes and measurement in childhood atopic dermatitis. , 2010, Immunology and allergy clinics of North America.
[60] J. Spergel,et al. From atopic dermatitis to asthma: the atopic march. , 2010, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.
[61] Muhammad Shahrukh,et al. Burden of skin diseases , 2009, Expert review of pharmacoeconomics & outcomes research.
[62] D. Stern. Benefit design innovations to manage specialty pharmaceuticals. , 2008, Journal of managed care pharmacy : JMCP.
[63] Timothy A. Dall,et al. The burden of skin diseases: 2004 a joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology. , 2006, Journal of the American Academy of Dermatology.
[64] P. Beattie,et al. A comparative study of impairment of quality of life in children with skin disease and children with other chronic childhood diseases , 2006, The British journal of dermatology.
[65] M. Boguniewicz,et al. Tacrolimus Ointment 0.03% Is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study , 2005, Pediatrics.
[66] J. Sung,et al. Health Plan Budget Impact Analysis for Pimecrolimus , 2005, Journal of Managed Care Pharmacy.
[67] M. Chren,et al. Effects of Atopic Dermatitis on Young American Children and Their Families , 2004, Pediatrics.
[68] P. Beattie,et al. Parental knowledge of topical therapies in the treatment of childhood atopic dermatitis , 2003, Clinical and experimental dermatology.
[69] M. Boguniewicz,et al. Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescents. , 2002, Journal of the American Academy of Dermatology.
[70] R. Langley,et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. , 2001, Journal of the American Academy of Dermatology.
[71] A. Fleischer,et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part II, safety. , 2001, Journal of the American Academy of Dermatology.